◀ Back to BCL3
BCL3 — CDKN1A
Text-mined interactions from Literome
DeHaan et al., Cancer Chemother Pharmacol 2001
:
In the ovarian carcinoma cell line A2780, cisplatin was shown to induce expression of p21WAF1, Gadd45 and Mdm2, but cisplatin had no effect on expression of Bax, Bcl-2,
Bcl-x1 , or Cyclin G. Inhibition of cisplatin induced ERK activity by PD98059
resulted in decreased levels of
p21WAF1 , Gadd45 and Mdm2
Liu et al., Int J Oncol 2009
(Leukemia) :
In identifying a molecular mechanism responsible for these effects MCT-1 alone and in combination with AZA
induced p15INK4b,
p21WAF1/CIP1 and Caspase-3 whilst attenuating
Bcl-XL expression
Festuccia et al., Endocr Relat Cancer 2009
(Disease Models, Animal...) :
In vivo, azacitidine ( 0.8 mg/kg i.p. ) reduced tumor proliferation and induced apoptosis in both xenografts upmodulating the expression of p16INKA, Bax, Bak,
p21/WAF1 , and p27/KIP1, and
inhibiting the activation of Akt activity and the expression of cyclin D1, Bcl-2, and
Bcl-XL
Gravina et al., Prostate 2010
(Neoplasms, Experimental...) :
This combined treatment up-regulated the expression of FasL, phospho-FADD, p16 ( INKA ), Bax, Bak, and
p21 ( WAF1 ), and
inhibited FLIP, Bcl-2, and
Bcl-XL expression
Vincent et al., FEBS Lett 2012
(Breast Neoplasms) :
Our studies reveal that NUPR1 confers growth benefit and chemoresistance by causing Akt mediated phosphorylation and subsequent cytoplasmic re-localization of
p21 and
activation of the anti-apoptotic
Bcl-xL protein